November 2022 PRIM&R research ethics roundup covers a new billion-dollar biomedical agency, the potential development of an mRNA vaccine against Ebola, lab-made red blood cells, and how red wine and green tea compounds could slow Alzheimer’s. Read more
More than 100 research trials are reported to be underway on coronavirus already. It remains essential to lean on prior conversations and learning to put us in a position to conduct the best, most ethical research we can in a time of crisis. Read more
This week’s Research Ethics Roundup highlights a Nature editorial that encourages researchers to push back against both public and private forms of censorship in research contracts, the National Institute of Health (NIH)’s Comparative Genomics Branch issues new study with implications for both human and dog disease research, the World Health Organization (WHO) speaks with Doctors Without Borders about using an experimental vaccine to target a new Ebola outbreak, and bioethicists' concern about stem cell researchers' failure to publish study results including discoveries on side effects. Read more
Global research issues take center stage in this week’s Research Ethics Roundup. Recently, the Chinese government announced new draft regulations on lab animal welfare. The results of the Ebola trials are being analyzed and French officials are launching an investigation after a fatal clinical trial.
Ebola's Thin Harvest: In this special report for Science, Jon Cohen and Martin Enserink report on the results of the Ebola clinical trials. They point out, "Never before had the disease affected enough people to allow researchers to test Ebola drugs and vaccines in a real-world setting." Unfortunately, the findings from many of these trials are unclear.
From Eli Lilly abandoning evacetrapib in the final stages of trials to the surprising placebo effect, this week’s Research Ethics Roundup shines the spotlight on clinical trials that could shape the future of research.
Gene Editing Record Smashed in Pigs: A team from Harvard Medical School, led by geneticist George Church, has used CRISPR technology to modify more than 20 genes in pig embryo and deactivate more than 60 viruses that could cause disease in human [...] Read more
